Almandeel, T.; Khan, M.A.; Algethami, A.; Alaboud, M.S.; Alkathiri, M.A.; Aseeri, M.; Absi, A.; Almansour, M.; Alotaibi, A.
Real-World Evidence Assessing the Safety of Administering Intravenous Rituximab Biosimilar in the First Cycle and Subcutaneous Rituximab in Subsequent Cycles in B-Cell Lymphoma Patients. Pharmacy 2025, 13, 83.
https://doi.org/10.3390/pharmacy13030083
AMA Style
Almandeel T, Khan MA, Algethami A, Alaboud MS, Alkathiri MA, Aseeri M, Absi A, Almansour M, Alotaibi A.
Real-World Evidence Assessing the Safety of Administering Intravenous Rituximab Biosimilar in the First Cycle and Subcutaneous Rituximab in Subsequent Cycles in B-Cell Lymphoma Patients. Pharmacy. 2025; 13(3):83.
https://doi.org/10.3390/pharmacy13030083
Chicago/Turabian Style
Almandeel, Tamather, Mansoor Ahmed Khan, Ashwag Algethami, Mashael S. Alaboud, Munirah A. Alkathiri, Mohammed Aseeri, Ahmed Absi, Mubarak Almansour, and Abdullah Alotaibi.
2025. "Real-World Evidence Assessing the Safety of Administering Intravenous Rituximab Biosimilar in the First Cycle and Subcutaneous Rituximab in Subsequent Cycles in B-Cell Lymphoma Patients" Pharmacy 13, no. 3: 83.
https://doi.org/10.3390/pharmacy13030083
APA Style
Almandeel, T., Khan, M. A., Algethami, A., Alaboud, M. S., Alkathiri, M. A., Aseeri, M., Absi, A., Almansour, M., & Alotaibi, A.
(2025). Real-World Evidence Assessing the Safety of Administering Intravenous Rituximab Biosimilar in the First Cycle and Subcutaneous Rituximab in Subsequent Cycles in B-Cell Lymphoma Patients. Pharmacy, 13(3), 83.
https://doi.org/10.3390/pharmacy13030083
